ConductScience.org, home

Comparison · NCT01973205-72f47de4

Acetaminophen 250 mg and Aspirin 250 mg vs Placebo: Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Acetaminophen 250 mg and Aspirin 250 mg vs Placebo: Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment. Trial comparisons, record NCT01973205-72f47de4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01973205-72f47de4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4070.360.456wilson
Risk in group 20.3450.3010.393wilson
Risk difference, group 1 minus group 20.0614-0.005080.127newcombe hybrid score
Risk ratio, group 1 over group 21.180.9861.41log
Odds ratio, group 1 over group 21.30.9781.73log
Number needed to treat, for one more participant with the outcome on Acetaminophen 250 mg and Aspirin 250 mg than on Placebo16.3from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Acetaminophen 250 mg and Aspirin 250 mg2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg~Acetaminophen 250 mg and Aspirin 250 mg: 2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg164403OG001
Group 2Placebo2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets~Placebo: 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets142411OG000

Outcome

Type
SECONDARY
Title
Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment.
Description
Number of subjects who are free of phonophobia at the 2-hour assessment.
Time frame
2 hours
Population
Number of participants analyzed includes only subjects who treated a migraine (AA: N=408, Placebo: N = 415) and had a non-missing phonophobia free status at 2 hours (AA: N=403, Placebo: N = 411).

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine
NCT number
NCT01973205
Phases
PHASE3
Conditions
Acute Migraine
Interventions
Acetaminophen 250 mg and Aspirin 250 mg, Placebo
Lead sponsor
Novartis
Results first posted
2015-06-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01973205-72f47de4